You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
一品紅(300723.SZ):以3500萬元對創新藥研發公司分迪藥業進行增資
格隆匯 05-12 17:23

格隆匯5月12日丨一品紅(300723.SZ)公佈,公司於2021512日召開了第二屆董事會第三十二次會議,審議通過了《關於全資子公司對外投資的議案》,同意子公司廣州瑞奧生物醫藥科技有限公司(“瑞奧生物”)以自有資3500萬元對成都分迪藥業有限公司(“分迪藥業”)進行增資,增資完成後,瑞奧生物持有其25%的股權。根據公司章程,該議案無需公司股東大會審議。

分迪藥業作為一家致力於開發治療癌症和病毒感染性疾病的創新藥研發公司,擁有世界領先的PRODED蛋白降解藥物開發技術平台,將人工智能(AI)藥物篩選、靶向蛋白降解嵌合體(PROTAC)技術和分子膠技術相融合,可快速推進靶向蛋白降解小分子重磅新藥的研發上市。

分迪藥業是國內靶向蛋白質降解技術分子膠技術的領先企在海外市場,美國Arvinas公司和C4 Therapeutics公司分別是該領域的開創者,其基於上述技術各有重磅產品處於臨牀研究階段。從事分子膠技術開發的瑞士生物技術公司Monte Rosa Therapeutics成立於2018年,在2020-2021年度共進行三輪融資,金額合計高達2.235美元

分迪藥業是一家致力開發治療癌症和病毒感染性疾病的創新藥研發公司,通過與其合作,公司可以藉助PRODED蛋白降解藥物開發技術平台,快速切入治療癌症和病毒感染性疾病的靶向蛋白降解小分子新藥領域,加快公司創新藥佈局,提高公司在創新藥領域的核心競爭力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account